BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7525427)

  • 1. The prognostic significance of urinary beta core fragment in premenopausal women with carcinoma of the cervix.
    Carter PG; Iles RK; Neven P; Ind TE; Shepherd JH; Chard T
    Gynecol Oncol; 1994 Nov; 55(2):271-6. PubMed ID: 7525427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers.
    Cole LA; Wang YX; Elliott M; Latif M; Chambers JT; Chambers SK; Schwartz PE
    Cancer Res; 1988 Mar; 48(5):1356-60. PubMed ID: 3342414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report.
    Cole LA; Tanaka A; Kim GS; Park SY; Koh MW; Schwartz PE; Chambers JT; Nam JH
    Gynecol Oncol; 1996 Feb; 60(2):264-70. PubMed ID: 8631549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-core fragment of human chorionic gonadotropin in cervical intraepithelial neoplasia (CIN).
    Norman RJ; de Medeiros S; Amato F; Davis G; Davy M
    Gynecol Oncol; 1993 Apr; 49(1):16-8. PubMed ID: 8482553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Assessment of urinary beta-core fragment of hCG as a tumor marker of cervical cancer].
    Kinugasa M; Nishimura R; Hasegawa K; Okamura M; Kimura A; Ohtsu F; Takeuchi K
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Feb; 44(2):188-94. PubMed ID: 1545171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of highly sensitive immunoassays to measure human chorionic gonadotropin, its beta-subunit, and beta core fragment in the urine: application to malignancies.
    O'Connor JF; Schlatterer JP; Birken S; Krichevsky A; Armstrong EG; McMahon D; Canfield RE
    Cancer Res; 1988 Mar; 48(5):1361-6. PubMed ID: 2449279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
    Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
    Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The measurement of urinary beta core fragment in conjunction with serum CA125 does not aid the differentiation of malignant from benign pelvic masses.
    Carter PG; Iles RK; Neven P; Davies AP; Shepherd JH; Chard T
    Gynecol Oncol; 1993 Dec; 51(3):368-71. PubMed ID: 8112647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of highly sensitive enzyme immunoassay to measure urinary beta-core fragment in patients with gynecological cancer].
    Nishimura R; Kobayashi K; Katsuno M; Kobayashi T
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Feb; 42(2):143-8. PubMed ID: 1690253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UGP in urogenital disorders: Egyptian experience.
    el-Ahmady O; Halim AB; Gad M; Walker R
    Anticancer Res; 1996; 16(4B):2301-8. PubMed ID: 8694560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary concentrations of beta core fragment of hCG throughout pregnancy.
    de Medeiros SF; Amato F; Matthews CD; Norman RJ
    Obstet Gynecol; 1992 Aug; 80(2):223-8. PubMed ID: 1378955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies.
    Walker R; Crebbin V; Stern J; Scudder S; Schwartz P
    Anticancer Res; 1994; 14(5A):1703-9. PubMed ID: 7847804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Following metastatic placental site trophoblastic tumor with urine beta-core fragment.
    Rinne K; Shahabi S; Cole L
    Gynecol Oncol; 1999 Aug; 74(2):302-3. PubMed ID: 10419751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining beta-core fragment and total oestriol measurements to test for Down syndrome pregnancies.
    Cole LA; Acuna E; Isozaki T; Palomaki GE; Bahado-Singh RO; Mahoney MO
    Prenat Diagn; 1997 Dec; 17(12):1125-33. PubMed ID: 9467809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology.
    Schwartz PE; Cracchiolo BM; Cole LA
    Anticancer Res; 1996; 16(4B):2135-9. PubMed ID: 8694533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UGP--a tumor marker of gynecologic and breast malignancies? Specificity and sensitivity in pretherapeutic patients and the influence of hormonal substitution on the expression of UGP.
    Schwarz-Roeger U; Petzoldt B; Waldschmidt R; Walker RP; Bauknecht T; Kiechle M
    Anticancer Res; 1997; 17(4B):3041-5. PubMed ID: 9329597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of urinary beta core fragment of human chorionic gonadotrophin in women with vulvovaginal malignancy and its prognostic significance.
    Carter PG; Iles RK; Neven P; Ind TE; Shepherd JH; Chard T
    Br J Cancer; 1995 Feb; 71(2):350-3. PubMed ID: 7530986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine free beta hCG and beta core in pregnancies affected by Down's syndrome.
    Spencer K; Aitken DA; Macri JN; Buchanan PD
    Prenat Diagn; 1996 Jul; 16(7):605-13. PubMed ID: 8843469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary free beta hCG, beta core fragment and total oestriol as markers of Down syndrome in the second trimester of pregnancy.
    Hsu JJ; Spencer K; Aitken DA; Crossley J; Choi T; Ozaki M; Tazawa H
    Prenat Diagn; 1999 Feb; 19(2):146-58. PubMed ID: 10215073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers.
    Plebani M; Navaglia F; Basso D; De Paoli M; Nicoletto MO; Maraglino E; Torre GC
    Anticancer Res; 1996; 16(6B):3833-8. PubMed ID: 9042266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.